Predictive Value of Matrix Metalloproteinases and Their Inhibitors for Mortality in Septic Patients: A Cohort Study

Abstract

Purpose:

Over 170 biomarkers are being investigated regarding their prognostic and diagnostic accuracy in sepsis in order to find new tools to reduce morbidity and mortality. Matrix metalloproteinases (MMPs) and their inhibitors have been recently studied as promising new prognostic biomarkers in patients with sepsis. This study is aimed at determining the utility of several cutoff points of these biomarkers to predict mortality in patients with sepsis.

Materials and Methods:

A multicenter, prospective, analytic cohort study was performed in the metropolitan area of Bucaramanga, Colombia. A total of 289 patients with sepsis and septic shock were included. MMP-9, MMP-2, tissue inhibitor of metalloproteinase 1 (TIMP-1), TIMP-2, TIMP-1/MMP-9 ratio, and TIMP-2/MMP-2 ratio were determined in blood samples. Value ranges were correlated with mortality to estimate sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiving operating characteristic curve.

Results:

Sensitivity ranged from 33.3% (MMP-9/TIMP-1 ratio) to 60.6% (TIMP-1) and specificity varied from 38.8% (MMP-2/TIMP-2 ratio) to 58.5% (TIMP-1). As for predictive values, positive predictive value range was from 17.5% (MMP-9/TIMP-1 ratio) to 70.4% (MMP-2/TIMP-2 ratio), whereas negative predictive values were between 23.2% (MMP-2/TIMP-2 ratio) and 80.9% (TIMP-1). Finally, area under the curve scores ranged from 0.31 (MMP-9/TIMP-1 ratio) to 0.623 (TIMP-1).

Conclusion:

Although TIMP-1 showed higher sensitivity, specificity, and negative predictive value, with a representative population sample, we conclude that none of the evaluated biomarkers had significant predictive value for mortality.

Keywords

sepsis shock mortality matrix metalloproteinases matrix metalloproteinase-2 matrix metalloproteinase-9 matrix metalloproteinase inhibitors predictive value sensitivity and specificity biomarkers

Get full access to this article

View all access options for this article.

References

Singer

Deutschman

Seymour

, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801–810.

Vincent

Beumier

. Diagnostic and prognostic markers in sepsis. Expert Rev Anti Infect Ther. 2013;11(3):265–275.

Bouza

Lopez-Cuadrado

Saz-Parkinson

Amate-Blanco

. Epidemiology and recent trends of severe sepsis in Spain: a nationwide population-based analysis (2006-2011). BMC Infect Dis. 2014;14:3863.

Kaukonen

Bailey

Suzuki

Pilcher

Bellomo

. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311(13):1308–1316.

Leon

Hoyos

Barrera

, et al. Clinical course of sepsis, severe sepsis, and septic shock in a cohort of infected patients from ten Colombian hospitals. BMC Infect Dis. 2013;13:345.

Mayr

Yende

Angus

. Epidemiology of severe sepsis. Virulence. 2014;5(1):4–11.

Rhodes

Evans

Alhazzani

, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377.

Gaieski

Edwards

Kallan

Carr

. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41(5):1167–1174.

Birkedal-Hansen

Moore

Bodden

, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4(2):197–250.

10.

Cohen

Vincent

Adhikari

, et al. Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15(5):581–614.

11.

Kumar

Chaudhari

Kumar

. Biomarkers of sepsis: recent advancements. Apollo Med. 2015;12(4):239–242.

12.

Prucha

Bellingan

Zazula

. Sepsis biomarkers. Clin Chim Acta. 2015;440:97–103.

13.

Samraj

Zingarelli

Wong

. Role of biomarkers in sepsis care. Shock. 2013;40(5):358–365.

14.

Ali

MAM

Fan

Schulz

. Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc Med. 2011;21(4):112–118.

15.

Arpino

Brock

Gill

. The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol. 2015;44-46:247–254.

16.

Aschner

Zemans

Yamashita

Downey

. Matrix metalloproteinases and protein tyrosine kinases: potential novel targets in acute lung injury and ARDS. Chest. 2014;146(4):1081–1091.

17.

Davey

McAuley

O’Kane

. Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair. Eur Respir J. 2011;38(4):959–970.

18.

Houghton

. Matrix metalloproteinases in destructive lung disease. Matrix Biol. 2015;44-46:167–174.

19.

Lalu

Cena

Chowdhury

Lam

Schulz

. Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction. Br J Pharmacol. 2006;149(1):31–42.

20.

Bojic

Kotur-Stevuljevic

Kalezic

, et al. Diagnostic value of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis-associated acute kidney injury. Tohoku J Exp Med. 2015;237(2):103–109.

21.

Maitra

Bhaduri

Valane

Tervahartiala

Sorsa

Ramamurthy

. Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. Shock. 2003;20(3):280–285.

22.

Lauhio

Hastbacka

Pettila

, et al. Serum MMP-8, -9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res. 2011;64(6):590–594.

23.

Lorente

Martin

Sole-Violan

, et al. Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio. PLoS One. 2014;9(4):e94318.

24.

Nino

Serrano

Nino

, et al. TIMP1 and MMP9 are predictors of mortality in septic patients in the emergency department and intensive care unit unlike MMP9/TIMP1 ratio: multivariate model. PLoS One. 2017;12(2):e0171191.

25.

D’Hoore

Sicotte

Tilquin

. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med. 1993;32(5):382–387.

26.

Knaus

Draper

Wagner

Zimmerman

. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818–829.

27.

Vincent

Moreno

Takala

, et al. The SOFA (Sepsis-Related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med. 1996;22(7):707–710.

28.

Cho

Choi

. Biomarkers of sepsis. Infect Chemother. 2014;46(1):1–12.

29.

Galliera

Tacchini

Corsi Romanelli

. Matrix metalloproteinases as biomarkers of disease: updates and new insights. Clin Chem Lab Med. 2015;53(3):349–355.

30.

Sivula

Hastbacka

Kuitunen

, et al. Systemic matrix metalloproteinase-8 and tissue inhibitor of metalloproteinases-1 levels in severe sepsis-associated coagulopathy. Acta Anaesthesiol Scand. 2015;59(2):176–184.

31.

de Souza

Schulz

da Silva-Santos

. Matrix metalloproteinase inhibitors prevent sepsis-induced refractoriness to vasoconstrictors in the cecal ligation and puncture model in rats. Eur J Pharmacol. 2015;765:164–170.

32.

Castro

Cena

Cho

Walsh

Schulz

. Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats. Arterioscler Thromb Vasc Biol. 2012;32(3):662–668.

33.

Levey

. Measurement of renal function in chronic renal disease. Kidney Int. 1990;38(1):167.

34.

Dossetor

JB.

Creatininemia versus uremia. The relative significance of blood urea nitrogen and serum creatinine concentrations in azotemia. Ann Intern Med. 1966;65(6):1287.

35.

Chertow

Burdick

Honour

Bonventre

Bates

. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365–3370.

36.

Alobaidi

Basu

Goldstein

Bagshaw

. Sepsis-associated acute kidney injury. Semin Nephrol. 2015;35(1):2–11.

37.

Khwaja

. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–c184.

38.

Hoffmann

Brueckmann

Borggrefe

. Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis? Crit Care. 2009;13(6):1006.

39.

Lorente

Martin

Labarta

, et al. Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. Crit Care. 2009;13(5):R158.

40.

Wang

Zhang

Zhao

Dong

. Diagnostic and prognostic value of neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinases-1 for sepsis in the emergency department: an observational study. Crit Care. 2014;18(6):634.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.21 MB